Table 1.
Baseline Characteristics
| Variable | AF Group (n = 44) | Control Group (n = 44) | P Value |
|---|---|---|---|
| Demographic | |||
| Male sex, n (%) | 27 (61%) | 27 (61%) | Matched |
| Age (years) | 67.2 ± 8 | 67.2 ± 8 | Matched |
| Clinical | |||
| Diabetes, n (%) | 8 (18%) | 11 (25%) | 0.43 |
| Hypercholesterolemia, n (%) | 24 (54%) | 27 (61%) | 0.51 |
| BMI | 27.9 ± 4 | 27.6 ± 4 | 0.71 |
| Systolic BP (mmHg) | 124 ± 16 | 121 ± 16 | 0.42 |
| Diastolic BP (mmHg) | 73 ± 10 | 71 ± 8 | 0.37 |
| LV dysfunction, n (%) | 10 (23%) | 9 (20%) | 0.79 |
| Drug therapy | |||
| Beta‐blockers, n (%) | 17 (39%) | 25 (57%) | 0.09 |
| ACE‐inhibitors or ARB, n (%) | 29 (66%) | 36 (82%) | |
| Anti‐arrhythmic drugs, n (%) | 18 (41%) | 2 (4%) | |
| Flecainide | 2 (5%) | 0 | |
| Propafenone | 3 (7%) | 0 | 0.09 |
| Amiodarone | 11 (25%) | 2 (4%) | <0.001 |
| Dronedarone | 1 (2%) | 0 | |
| Sotalol | 1 (2%) | 0 | |